Quantib obtains CE mark for their AI prostate solution

April 08, 2021
Rotterdam, The Netherlands – April 7, 2021 – Quantib, a market leader in artificial intelligence solutions for precision diagnosis, announced today that their Quantib® Prostate solution has successfully obtained class IIb CE marking under the new MDR laws. After having received FDA clearance for clinical use in the United States in October 2020, this AI solution is now available for the European market.

Quantib® Prostate, leveraging the power of deep learning algorithms, dramatically improves the MRI prostate reporting workflow accessible directly from the radiologist's reading station. Moreover, the solution comes with a suite of tools to improve reporting quality and speed: including AI-based volumetry and PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, classification and standardized reporting to facilitate easy and comprehensive communication of results.
"Many European hospitals were waiting for this moment and it is fantastic that we can now bring this solution that is so well received in the US to radiologists across Europe." said Arthur Post Uiterweer, CEO of Quantib.

New healthcare guidelines introduced in 2019 and 2020 make an MRI scan of the prostate a standard procedure for every patient that requires a prostate biopsy. Triple digit growth in MRI prostate scans is the result in the coming years, however, there are not enough expert radiologists to report all these extra scans.

Sapienza University Hospital in Rome is one of the first sites in Europe that purchased and received an installation of Quantib Prostate. "At Sapienza we are always eager to discover and experiment with new AI tools to further promote research in imaging", said Prof. Valeria Panebianco, Radiologist at Sapienza University Hospital.

About Quantib
Quantib's AI radiology solutions enable faster and more accurate diagnosis by quickly identifying abnormalities, supporting adequate and timely patient care. Using state-of-the-art artificial intelligence techniques, Quantib's software advances the diagnostic pathway by providing FDA-cleared and CE marked solutions related to neurodegeneration, prostate cancer, breast cancer and many more. All deployed through our Quantib AI Node platform enabling seamless workflow integration and rapid regulatory clearance.